Small cap im­munother­a­py play­er Zio­pharm faces an ac­tivist at­tack, re­bukes call for board seats

Zio­pharm On­col­o­gy is at­tempt­ing to fend off an ac­tivist at­tack.

The Boston-based biotech sent a let­ter to share­hold­ers Mon­day urg­ing them to re­ject the pro­pos­als …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER